BCL2 and Miyoshi myopathy: The prognostic impact of t(11;14) is currently being discussed in the era of novel therapies, and this cytogenetic abnormality is considered as a novel predictive marker in MM as patients with t(11;14) are sensitive to venetoclax, a highly selective inhibitor of BCL-2 [16,17].